Dr. Kuykendall discusses the important quality of life aspects to consider when treating PV patients and the specific strategies or treatments he uses to help preserve overall QoL throughout the disease course.
Andrew Kuykendall, MD
Andrew Kuykendall, MD, is an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center.
Articles by Andrew Kuykendall, MD
Dr. Kuykendall explains how he monitors PV patients for thrombosis risk, which hematological values concern him most, and his approach if hematocrit rises above 45%.
Dr. Kuykendall shares his experience using peginterferon or ropeginterferon for PV treatment, including the biggest challenges, limitations, and managing safety/tolerability issues with these agents.
Dr. Kuykendall discusses the efficacy and safety findings from studies like MAJIC-PV and PROUD-PV, and how they influence his treatment choices for PV.
Dr. Kuykendall comments on the high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in the RESPONSE trial for hydroxyurea-resistant/intolerant PV, and how these efficacy findings inform his treatment choices.
Dr. Kuykendall explains the factors he considers when deciding on initial therapy for advanced PV patients, including comorbidities, individual patient factors like age and symptoms, and weighing the risks and benefits of different treatment options.
Dr. Kuykendall discusses his initial impressions of the case, how it compares to typical advanced polycythemia vera presentations, and typical risk factors seen in PV patients.
Andrew Kuykendall, MD, discusses recent approvals seen for patients with myeloproliferative neoplasms.
Andrew Kuykendall, MD, discusses some of the recent changes there have been for patients with myeloproliferative neoplasms.
Andrew Kuykendall, MD, discusses the current treatment landscape for the patients with myelofibrosis and how this evolved over the last decade.
Andrew Kuykendall, MD, discusses the background to the JAK2 inhibitor fedratinib (Inrebic), which was approved by the FDA in August 2019 for the treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including post–polycythemia vera or post–essential thrombocythemia MF.